Search | Clinical Trials Finder

Conditions: NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric Cancer (GC), Endometrial Cancer
Interventions: TS-104; Drug
Lead sponsor: TwoStep Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Maumee, Ohio • Portland, Oregon • Fairfax, Virginia

Conditions: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Interventions: TAS6417, CYP Cocktail, Transporter Cocktail; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more

Conditions: Lung Cancer
Interventions: cisplatin, irinotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 8
States / cities: Millville, New Jersey • Mount Holly, New Jersey • Red Bank, New Jersey + 5 more

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: NHT102, DryNeb; Drug · Device
Lead sponsor: Nob Hill Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Non-Small Cell Lung Cancer
Interventions: Cabozantinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Non-Small-Cell Lung Cancer
Interventions: Pembrolizumab; Drug
Lead sponsor: Greg Durm, MD; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more

Conditions: Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
Interventions: PRT2527; Drug
Lead sponsor: Prelude Therapeutics Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Interventions: CC-223, erlotinib, CC-223, oral azacitidine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • New York, New York + 4 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Squamous Non-small Cell Lung Cancer
Interventions: Buparlisib, Buparlisib matching placebo, Docetaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Fayetteville, Arkansas • Tampa, Florida • Worcester, Massachusetts + 1 more

Conditions: Advanced or Metastatic NSCLC
Interventions: Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Interventions: amifostine trihydrate, cisplatin, docetaxel; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lung Cancer
Interventions: Questionnaire, Interactive Voice Response Telephone System, IVR Plus Triage; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms
Interventions: GSK3901961, GSK3845097, GSK4427296, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: Jacksonville, Florida • Atlanta, Georgia • Westwood, Kansas + 5 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 62
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 53 more

Conditions: Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, Metastatic NSCLC
Interventions: Cabazitaxel-XRP6258 (3-week cycle), Cabazitaxel-XRP6258 (5-week cycle); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Birmingham, Alabama • Atlanta, Georgia

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: docetaxel, placebo, nintedanib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 9
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Highland, California + 6 more

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 34
States / cities: Fayetteville, Arkansas • Duarte, California • Fountain Valley, California + 29 more

Conditions: Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions: aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, sargramostim, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: batabulin sodium; Drug
Lead sponsor: Tularik; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: San Francisco, California • Nashville, Tennessee

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: fianlimab, cemiplimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Tucson, Arizona • Yuma, Arizona • Redlands, California + 20 more

Conditions: Advanced Solid Tumors
Interventions: INCB099280, adagrasib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Greeley, Colorado • Detroit, Michigan + 2 more

Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions: FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab; Drug · Combination Product
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more

Conditions: Locally Advanced Non-small Cell Lung Cancer
Interventions: vorinostat; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 3
States / cities: Tampa, Florida • Philadelphia, Pennsylvania • Charleston, South Carolina

Search by objective public record fields.

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Phase II Trial of Continuation Therapy in Advanced NSCLC

A Study of PRT2527 in Participants With Advanced Solid Tumors

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer

Interactive Voice Response (IVR) Symptom Assessment in Non-Small Cell Lung Cancer (NSCLC) Patients

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)